GSK’s commitment to the UK

GSK Chief executive Emma Walmsley stated the company plans to continue investing in its UK manufacturing base and will maintain research and advancement spending in the country at over £1.5 billion annually. This commitment comes as a counterpoint to a recent trend of pharmaceutical companies reducing or diverting investment from the UK.

Growing Concerns Over UK Pharma Investment

The pharmaceutical sector in the UK is facing significant disruption, with drugmakers pausing or cancelling nearly £2 billion in planned investments this year. This is largely attributed to threats of substantial tariffs – perhaps as high as 250% – on pharmaceutical imports from the UK into the United States.

GSK is not alone in reassessing its UK presence.Recent announcements signal a broader shift in investment priorities.

Recent Investment Withdrawals

Last week, US pharmaceutical company Merck, known as MSD outside of North America, announced the cancellation of its £1 billion London research center as reported by the BBC. Shortly after, astrazeneca halted its planned £200 million expansion of its research facilities in Cambridge, also according to the BBC.

The Impact of US Tariffs

The potential imposition of high tariffs by the US is a key driver of the recent investment shifts. The US government has indicated it may implement tariffs as a response to disputes over drug pricing and market access. This creates significant financial risk for companies relying on exports to the US market.

The situation highlights the vulnerability of the UK pharmaceutical industry to international trade policies and the importance of maintaining strong trade relationships.

Pharmaceutical Investment in the UK: A Timeline